Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    Psychotropic Medication Use Mediates Obesity in Patients With Mood, Anxiety Disorders: Presented at ADAA - (DGDispatch)
    Study Confirms Reliability, Validity of Quick-Scoring Anxiety Scale - (DGNews)
    Antidepressant Initiation May Raise Risk for Anxiety in Depressed Patients: Presented at ADAA - (DGDispatch)
    Intensive Weekend Treatment May Work for Veterans Returning With Panic Disorder: Presented at ADAA - (DGDispatch)
    Gamma Knife Ventral Capsulotomy for Intractable OCD Safe, but Further Study Needed: Presented at ADAA - (DGDispatch)

    News archive

     Recent webcasts/CME - Anxiety

    Webcasts/CME archive

     Recent cases - Anxiety
      Tomophobia, The Phobic Fear Caused By An Invasive Medical Procedure - An Emerging Anxiety Disorder: A Case Report
      Diagnosing and Managing Post-Traumatic Stress Disorder
      Chronic Dizziness Presenting in a Patient with Panic Disorder: Response to Imipramine
      Aripiprazole Augmentation in Poor Insight Obsessive-Compulsive Disorder: A Case Report
      Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report

      Cases archive
        




      my personal edition > anxiety > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Duloxetine is Effective for Anxiety: Presented at ADAA

      By Jill Stein

      ST.LOUIS, MO -- April 2, 2007 -- Duloxetine decreases the severity of anxiety symptoms in patients with generalised anxiety disorder (GAD) and also improves patients' functioning, according to results presented here at the 27th Annual Meeting of the Anxiety Disorders Association of America (ADAA).

      Christer Allgulander, MD, associate professor, psychiatry division, Karolinska Institute, Stockholm, Sweden, reported data from a pooled analysis of 3 randomised, double-blind, placebo-controlled trials of the serotononergic noradrenergic reuptake inhibitor (SNRI) duloxetine with a total of 1,163 patients.

      Two studies had a 10-week flexible-dose 60 to 120 mg/day regimen, and 1 study had a 9-week fixed-dose 60 or 120 mg/d regimen.

      The primary efficacy measure was mean change from baseline to endpoint in Hamilton Anxiety Scale (HAMA) total score. Secondary efficacy measures included HAMA Psychic and Somatic factor score, HAMA response and remission rate, Hospital Anxiety Depression Scale (HADS) subscale score, and Clinician and Patient Global Impressions-Improvement scale.

      Response was defined as 50% or greater reduction in HAMA total score from baseline to endpoint, and remission was defined as HAMA total score of 7 or less at endpoint.

      Results showed that the intent-to-treat duloxetine-treated patients had a significantly greater mean reduction on the HAMA total score compared with placebo-treated patients (M = -11.1 vs M = -.80, P less than or equal to .001).On all secondary measures, the duloxetine group had significantly greater improvement than the placebo group.

      Compared with placebo, duloxetine patients had greater functional improvement as demonstrated by decreases in Sheehan Disability Scale global functioning score (P less than or equal to .001).

      Response and remission rates in duloxetine-treated patients (51% and 30%, respectively) were higher than in placebo-treated patients (33% and 20%, respectively (P < .001 for both comparisons).

      Overall, 34% of the duloxetine group and 31% of the placebo group dropped out of the study prematurely. Duloxetine-treated patients usually withdrew because of adverse events (P less than or equal to .001), and placebo patients withdrew because of a lack of efficacy (P < .001).

      Nausea was the most common treatment-emergent event.

      "The results demonstrate that duloxetine is an effective pharmacologic intervention for generalised anxiety disorder," Dr. Allgulander said in a presentation on March 31st.

      The study was sponsored by Lilly Research Laboratories in Indianapolis, Indiana.


      [Presentation title: Duloxetine as an Effective Treatment for Adults With Generalized Anxiety Disorder. Abstract P69]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send